# CCLDO earnings call intelligence

LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/CCLDO) · [Earnings tab](https://www.lopjlb.com/stock/CCLDO?tab=earnings)

Updated: 2026-09-07T05:47:16

Quarters analyzed: 8

## Cross-quarter narrative

Across the eight earnings calls, CareCloud’s story shifted from a cash‑rich, debt‑free balance sheet focused on resuming preferred dividends (Q3 2024) to a growth engine powered by AI‑driven products, strategic non‑dilutive acquisitions, and a simplified capital structure (Q1 2026). Early calls highlighted modest revenue pressure but strong free‑cash‑flow generation and the launch of CirrusAI features. By Q4 2024 the company announced a series‑A preferred conversion and a pipeline of AI solutions, while warning that a lack of acquisitions and early‑stage AI adoption could curb momentum. Subsequent quarters showed accelerating AI adoption, record profitability, and the delivery of key milestones such as the AI Center of Excellence, StratusAI Front Desk Agent, and the Medsphere and MAP App acquisitions. Margin expansion accelerated through AI automation, though integration costs and amortization created temporary pressure in Q1 2026. Guidance moved from vague to raised, reflecting confidence in AI‑enabled revenue streams. Persistent concerns include integration risk, AI adoption uncertainty, and competitive pressure, while earlier fears around dividend obligations and revenue decline faded as cash flow strengthened.

## Latest CallCard · Q2

**Guidance:** vague

**Tone:** mgmt 0 · Q&A pressure 0 · divergence 0

## Quarter one-liners

- **2026 Q2:** —
- **2026 Q1:** CareCloud Q1 2026 showed 13% revenue growth, AI platform scaling, and a capital structure simplification while reaffirming full‑year guidance despite integration costs.
- **2025 Q4:** CareCloud reported transformational 2025 results with revenue up 9%, first full‑year positive EPS, strong free cash flow, multiple non‑dilutive acquisitions and a commercial AI platform launch, and set 2026 guidance that management says is achievable.
- **2025 Q3:** CareCloud Q3 2025 showed profitable growth, raised full‑year revenue guidance, highlighted AI milestones and completed Medsphere and Map App acquisitions while focusing on cross‑sell, AI front‑desk rollout and margin expansion.
- **2025 Q2:** CareCloud posted its first positive GAAP EPS, reaffirmed 2025 guidance, highlighted AI Center of Excellence progress, new ONC‑certified CAH platform and strong free cash flow while pursuing AI‑driven products and acquisitions.
- **2025 Q1:** —
- **2024 Q4:** CareCloud posted record profitability, strong free cash flow and a capital-structure conversion, while guiding 2025 revenue $111-$114M and EPS $0.10-$0.13 amid AI-driven growth.
- **2024 Q3:** CareCloud paid off $10M credit line, targets March 2025 preferred dividend resumption, Q3 EBITDA up 111% YoY, FCF $10.3M YTD up 328%, revenue slightly down due to medSR non-recurring; advancing CirrusAI and RPM for 2025 growth.

## Theme arcs

- **AI product rollout** (improving): From early traction and on‑track status to multiple AI solutions delivered and revenue impact growing.
- **Margin expansion** (improving): AI automation and labor arbitrage drove margin gains, offset temporarily by integration costs in 2026.
- **Acquisition strategy** (stable): Non‑dilutive acquisitions (Medsphere, MAP App) delivered as planned, supporting cross‑sell.
- **Capital structure** (improving): Series A conversion, credit facility, and Series B redemption simplified balance sheet and funded growth.
- **Guidance confidence** (improving): Guidance moved from vague to raised as AI revenue contributions materialized.

## Fear persistence

- **Integration risk** [recurring]: Cited from Q2 2025 through Q1 2026 as acquisitions integrate.
- **AI adoption/monetization risk** [recurring]: Early‑stage revenue contribution concerns appear Q2 2025 onward.
- **Competitive pressure** [recurring]: Mentioned Q3 2025 and Q4 2025 regarding AI voice‑assistant rivals.
- **Credit facility repayment risk** [resolved]: Raised in Q3 2025, not mentioned later.
- **Regulatory risk** [resolved]: Highlighted Q4 2025, absent in later calls.
- **Market volatility** [resolved]: Noted Q4 2025, not repeated.
- **Acquisition dependence** [resolved]: Raised Q4 2025, later mitigated by completed deals.
- **Dividend obligations** [resolved]: Early concern Q4 2024, faded as cash flow strengthened.
- **Revenue decline** [resolved]: Observed Q4 2024, later revenue grew.
- **Seasonality** [new]: Seasonal margin pressure flagged Q1 2026.

## Guidance path

2024 Q3:vague → 2024 Q4:maintained → 2025 Q1:vague → 2025 Q2:maintained → 2025 Q3:raised → 2025 Q4:maintained → 2026 Q1:maintained → 2026 Q2:vague

---

Research context only. Not personalized investment advice.

API: `GET /bff/api/bigfive/earnings-intel/CCLDO`